XFOR — X4 Pharmaceuticals Inc · catalysts, narrative & risks

X4 Pharmaceuticals (Nasdaq: XFOR) — Point-in-Time Research as of 2026-11-01

Company snapshot. X4 Pharmaceuticals is a Boston-headquartered clinical-stage biotechnology company centered on the CXCR4 pathway and rare immune/hematologic diseases. Its lead drug, mavorixafor, is marketed in the U.S. and EU as XOLREMDI for WHIM syndrome [4][20]. As of the Oct 30, 2026 close, the stock traded around $3.35 with a market cap of ~$332M, a 52-week range of $2.43–$4.83, and trailing-twelve-month revenue of ~$15.85M against a net loss of ~$90.14M [16][20].